About Us

Developing novel drugs to treat inflammation

About the Company

Arch Biopartners is a late-stage clinical trial company focused on preventing inflammation and acute organ injury.

Arch is developing a platform of novel therapeutic drugs, led by LSALT peptide (Metablok), that are:
  • designed to inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP1) pathway and,
  • relevant for common organ injuries and diseases where organ inflammation is an unmet problem with no effective treatments in the market today.
About LSALT Peptide

LSALT peptide is a novel peptide drug candidate and DPEP1 inhibitor. In August 2019, a scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins published a paper in the journal (Cell 2019) describing a novel mechanism of action for organ inflammation. In the publication, DPEP1 was identified, for the first time, as a major leukocyte (white blood cell) adhesion receptor on the lung, liver and kidney endothelium. DPEP1 was also identified as the target of LSALT peptide, differing from typical anti-inflammatory drugs by targeting this novel adhesion receptor rather than targeting individual cytokines.

In 2024, the company is sponsoring a Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). The CS-AKI trial began dosing patients in March 2024. The trial began with three active hospital sites in Turkey with a hospital site in Canada also joining in March 2024. The complete study is planned to include up to 240 patients in Turkey, Canada and the United States.

Find out more about ongoing LSALT peptide development and clinical trials.

Arch Biopartners approach

Arch has a long history of working closely with the scientific community, universities and research institutions. The company’s mission is to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors.

An experienced group of scientists with an executive, board and advisors bringing deep scientific, pharmaceutical, biotechnology and corporate financial experience.
Science and Research
  • Current work on LSALT Peptide (Metablok) is directed by Arch’s larger Treatments for Inflammation Team, led by Dr. Daniel Muruve Ph. D. (Arch Biopartners CSO), Dr. Justin Macdonald Ph. D. and Dr. Arthur Lau Ph. D (Arch Biopartners Project Director) who are primarily based at the University of Calgary. Dr. David Luke, BScPhm, PharmD, is a Strategic Advisor working to support the Board of Directors and the company’s ongoing clinical trials with LSALT peptide
  • The DPEP1 Inflammation Pathway and LSALT Peptide were discovered by the Metablok team – Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D. and Jennifer Rahn B Sc., M Sc. at the University of Calgary.

The Arch science team also includes:

Executive, Board of Directors and Advisors
Find key information at the Investor Hub and please subscribe for the latest Investor News and Science alerts as treatments and technologies are developed and advanced.
Science and research
Browse journal publications and information about ongoing developments

Subscribe for email updates

Get email alerts when news is published
Please check the options for Investor News and Science Updates to receive additional information about events and publications

Press Release Archives